세계의 면역측정 분석기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Immunoassay Analyzers Market Trends:

The global Immunoassay analyzers market size was estimated at USD 7.18 billion in 2024 and is expected to grow at a CAGR of 4.13% from 2025 to 2030. The increasing prevalence of chronic diseases, including both infectious and non-infectious conditions, is a significant driver of market growth for immunoassay analyzers. As the burden of diseases such as cancer and cardiovascular conditions continues to rise, technological advancements and the application of immunoassay analyzers are expanding rapidly. These advancements play a crucial role in early diagnosis, disease monitoring, and treatment planning. The World Health Organization (WHO) reported approximately 20 million new cancer cases in 2022, with a projected increase in diagnoses reaching 53.5 million in the coming years. This surge in chronic illnesses is fueling the demand for innovative immunoassay solutions, leading companies to develop more advanced and effective diagnostic technologies.

The outbreak of the COVID-19 pandemic further emphasized the need for rapid and accurate diagnostic tools. The emergence of the SARS-CoV-2 virus created an urgent demand for accelerated diagnostic methods that could offer both precision and affordability. While RT-PCR tests were widely used for early detection, they were often considered expensive and resource-intensive. This led to the widespread deployment of immunoassay analyzers for detecting antibodies, providing a more cost-effective and efficient alternative. Companies responded swiftly to this demand by launching advanced immunoassay solutions. For instance, Agilent Technologies, Inc. introduced the Agilent Dako SARS-CoV-2 enzyme-linked immunoassay kit, designed to detect SARS-CoV-2 antibodies in human serum or plasma. The pandemic heightened awareness about the capabilities of immunoassay analyzers, accelerating technological developments and market expansion.

The increasing prevalence of chronic diseases has driven continuous advancements in immunoassay technologies. The emergence of new infectious diseases, growing concerns over antibiotic resistance, and the rising demand for personalized medicine have spurred the need for highly sensitive, specific, and rapid immunoassay tests. Various companies are investing in innovative solutions to meet these evolving healthcare needs. Diamond Diagnostics, for example, is committed to enhancing immunoassay diagnostics by manufacturing high-quality, cost-effective consumables and accessories for immunoassay analyzers. Such innovations contribute to the expansion of the market, ensuring that healthcare providers have access to reliable and advanced diagnostic tools.

In addition to technological advancements, strategic collaborations among key industry players are significantly contributing to market growth. Companies are increasingly forming partnerships to strengthen their immunoassay capabilities, support therapeutic advancements, and facilitate clinical adoption. A notable example is the collaboration between Beckman Coulter, Inc. and Fujirebio in July 2023. This partnership aims to enhance immunoassay applications in neurodegenerative disease research, clinical trials, routine diagnostics, and reimbursement processes. By combining expertise and resources, these collaborations are driving innovation and improving the accessibility of advanced diagnostic solutions.

Global Immunoassay Analyzers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global Immunoassay analyzers market report on the basis of product, application, end use, region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)
• Chemiluminescence Immunoassays (CLIA)
• Fluorescence Immunoassays (FIA)
• Radioimmunoassay
• Enzyme-Linked Immunoassay
• Consumables and Accessories
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Therapeutic Drug Monitoring
• Oncology
• Cardiology
• Endocrinology
• Infectious Disease Testing
• Autoimmune Disease
• Others
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Immunoassay Analyzers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence of chronic and infectious diseases
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Growing adoption of personalized products
    • 3.2.1.4. Growing investments and collaborations
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs and operational complexity
• 3.3. Immunoassay Analyzers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
• 3.4. Case Study

Chapter 4. Immunoassay Analyzers Market: Product Estimates & Trend Analysis

• 4.1. Products Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Immunoassay Analyzers Market: Product Movement Analysis
• 4.4. Immunoassay Analyzers Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.5. Chemiluminescence Immunoassays (CLIA)
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Fluorescence Immunoassays (FIA)
  • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Radioimmunoassay
  • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Enzyme-Linked Immunoassay
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. vConsumables and Accessories
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Consumables and Accessories
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunoassay Analyzers Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Immunoassay Analyzers Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Therapeutic Drug Monitoring
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Cardiology
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Endocrinology
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Infectious Disease Testing
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Autoimmune Disease
  • 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunoassay Analyzers Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Immunoassay Analyzers Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Hospitals & Clinics
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Diagnostic Laboratories
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Research Institutes
  • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunoassay Analyzers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. North America: SWOT Analysis
  • 7.5.2. U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/Reimbursement
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/Reimbursement
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/Reimbursement
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe: SWOT Analysis
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/Reimbursement
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/Reimbursement
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/Reimbursement
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/Reimbursement
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/Reimbursement
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/Reimbursement
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/Reimbursement
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework/Reimbursement
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/Reimbursement
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/Reimbursement
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/Reimbursement
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/Reimbursement
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/Reimbursement
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework/Reimbursement
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America: SWOT Analysis
  • 7.8.2. Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/Reimbursement
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/Reimbursement
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. MEA: SWOT Analysis
  • 7.9.2. South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/Reimbursement
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/Reimbursement
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/Reimbursement
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Siemens Healthineers AG
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Services benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. BIOMERIEUX
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Services benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. FAbbott
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Services benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. QuidelOrtho Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Services benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Sysmex Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Services benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. BD
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Services benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Thermo Fisher Scientific Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Services benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. F. Hoffmann-La Roche Ltd
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Services benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Beckman Coulter, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Services benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. DiaSorin S.p.A.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Services benchmarking
    • 8.3.13.4. Strategic initiatives